Document:

Exhibit 4.3

 

NEITHER THIS SECURITY NOR THE SECURITIES
INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION
OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE
SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF
THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN
WITH A FINANCIAL INSTITUTION THAT IS AN “ACCREDITED INVESTOR” AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT
OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

COMMON SHARE PURCHASE
WARRANT

 

GLOBUS MARITIME LIMITED

 

	Warrant Shares: [_______]	Issue Date: July ___, 2020

 

This COMMON SHARE PURCHASE
WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on
or after the Issue Date and on or prior to 5:00 p.m. (New York City time) on January [●], 2026 (the “Termination
Date”) but not thereafter, to subscribe for and purchase from Globus Maritime Limited, a Marshall Islands corporation
(the “Company”), up to ______ Common Shares (as subject to adjustment hereunder, the “Warrant Shares”). 
The purchase price of one Common Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

 

Section 1.     Definitions. 
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1.
Capitalized terms not otherwise defined in this Warrant shall have the meanings assigned to such terms in the Purchase Agreement.

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

 

“Bid
Price” means, for any date, the price determined by the first of the following clauses that applies: (a) if
the Common Shares are then listed or quoted on a Trading Market, the bid price of the Common Shares for the time in question
(or the nearest preceding date) on the Trading Market on which the Common Shares are then listed or quoted as reported by
Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)),
(b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Shares for such date (or
the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Shares are not then listed or quoted for
trading on OTCQB or OTCQX and if prices for the Common Shares are then reported on the Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Share so reported, or (d) in all other cases, the fair market value of a Common Share as determined by an independent
appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company.

 

    

     

    

 

“Business
Day” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; provided, however, for clarification, commercial banks shall not be deemed to
be authorized or required by law to remain closed due to “stay at home”, “shelter-in-place”, “non-essential
employee”  or any other similar orders or restrictions or the closure of any physical branch locations at the direction
of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks
in The City of New York generally are open for use by customers on such day.

 

“Commission”
means the United States Securities and Exchange Commission.

 

“Common Shares”
means the common shares of the Company, par value $0.004 per share, and any other class of securities into which such securities
may hereafter be reclassified or changed.

 

“Common Share
Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Shares, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common
Shares.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Purchase
Agreement” means that certain Securities Purchase Agreement, dated July 17 , 2020, among the Company and the Holders
signatory thereto.

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Subsidiary”
means any subsidiary of the Company, which is actively engaged in a trade or business, and shall, where applicable, also include
any direct or indirect subsidiary of the Company formed or acquired after the date hereof.

 

“Trading Day”
means a day on which the Common Shares are traded on a Trading Market.

 

“Trading Market”
means any of the following markets or exchanges on which the Common Shares are listed or quoted for trading on the date in question:
the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange
(or any successors to any of the foregoing).

 

“Transfer
Agent” means Computershare Inc. or its affiliate with offices located at 150 Royall Street, Canton, MA 02021, and any
successor transfer agent of the Company.

 

    2

     

    

 

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Shares are
then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Shares for such date (or the nearest
preceding date) on the Trading Market on which the Common Shares are then listed or quoted as reported by Bloomberg L.P. (based
on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is
not a Trading Market, the volume weighted average price of the Common Shares for such date (or the nearest preceding date) on OTCQB
or OTCQX as applicable, (c) if the Common Shares are not then listed or quoted for trading on OTCQB or OTCQX and if prices
for the Common Shares are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions
of reporting prices), the most recent bid price per Common Share so reported, or (d) in all other cases, the fair market value
of a Common Share as determined by an independent appraiser selected in good faith by the holders of a majority in interest of
the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

 

“Warrants”
means this Warrant and other Common Share Purchase Warrants issued by the Company on or around the Issue Date.

 

Section 2.     Exercise.

 

a)            Exercise
of Warrant.  Subject to the provisions of Section 2(e) herein, exercise of the purchase rights represented
by this Warrant may be made, in whole or in part, at any time or times on or after the Issue Date and on or before the
Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the
Notice of Exercise in the form annexed hereto (the “Notice of Exercise”).  Within the earlier of
(i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as
defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the
aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer in United States
dollars unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable
Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or
other type of guarantee or notarization) of any Notice of Exercise be required.  Notwithstanding anything herein to the
contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased
all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall
surrender this Warrant to the Company for cancellation within five (5) Trading Days of the date on which the final
Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the
total number of Warrant Shares available hereunder shall lower the outstanding number of Warrant Shares purchasable hereunder
in an amount equal to the applicable number of Warrant Shares purchased.  The Holder and the Company shall maintain
records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any
objection to any Notice of Exercise within one (1) Business Day of receipt of such notice.  The Holder and any
assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following
the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at
any given time may be less than the amount stated on the face hereof.

 

b)            Exercise
Price.  The exercise price per Common Share under this Warrant shall be $0.18, subject to adjustment hereunder
(the “Exercise Price”).

 

c)            Cashless
Exercise.  If at any time after the six month anniversary of the Issue Date there is no effective registration
statement registering, or the prospectus contained therein is not available for the resale of the Warrant Shares by the
Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a “cashless
exercise” in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by
dividing [(A-B) (X)] by (A), where:

 

(A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the
date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to
Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to
Section 2(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as defined in
Rule 600(b)(68) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the
option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of
Exercise or (z) the Bid Price of the Common Shares on the principal Trading Market as reported by Bloomberg L.P. as of
the time of the Holder’s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during
 “regular trading hours” on a Trading Day and is delivered within two (2) hours thereafter (including until
two (2) hours after the close of “regular trading hours” on a Trading Day) pursuant to
Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such
Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to
Section 2(a) hereof after the close of “regular trading hours” on such Trading Day;

 

(B) = the
Exercise Price of this Warrant, as adjusted hereunder; and

 

(X) = the number of Warrant Shares that would be issuable
upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise
rather than a cashless exercise.

 

    3

     

    

 

If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with
Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrant being
exercised and the holding period of this Warrant may be tacked on to the holding period of the Warrant Shares being
issued. The Company agrees not to take any position contrary to this Section 2(c).

 

Notwithstanding anything
herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant to
this Section 2(c).

 

d)            Mechanics
of Exercise.

 

i.            Delivery
of Warrant Shares Upon Exercise.  The Company shall cause the Warrant Shares purchased hereunder to be transmitted
by the Transfer Agent to the Holder by crediting the account of the Holder’s or its designee’s balance account
with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the
Company is then a participant in such system and either (A) there is an effective registration statement permitting the
issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible
for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming this Warrant is
being exercised via cashless exercise), and otherwise by physical delivery of a certificate, registered in the
Company’s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the
Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date
that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise,
provided that payment of the aggregate Exercise Price (other than in the instance of a cashless exercise) is received by the
Company one (1) Trading Day prior to such second Trading Day after the delivery of the Notice of Exercise, (ii) one
(1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days
comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise, provided that payment
of the aggregate Exercise Price (other than in the instance of a cashless exercise) is received by the Company one
(1) Trading Day prior to such number of Trading Days comprising the Standard Settlement Period after the delivery of the
Notice of Exercise (such date, the “Warrant Share Delivery Date”). Upon delivery of the Notice of
Exercise, the Holder shall be deemed, solely for purposes of Regulation SHO of the Securities Act, to have become the holder
of record of such Warrant Shares, irrespective of the date of delivery of such Warrant Shares, provided that payment of the
aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two
(2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery
of the Notice of Exercise. If the Company fails for any reason (other than failure of the Holder to timely deliver the
aggregate Exercise Price, unless the Warrant is validly exercised by means of a cashless exercise) to deliver or cause the
delivery to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company
shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to
such exercise (based on the VWAP of the Common Shares on the date of the applicable Notice of Exercise), $10 per Trading Day
(increasing to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading
Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The
Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains
outstanding and exercisable. As used herein, “Standard Settlement Period” means the standard settlement
period, expressed in a number of Trading Days, on the Company’s primary Trading Market with respect to the Common
Shares as in effect on the date of delivery of the Notice of Exercise.

 

ii.            Delivery
of New Warrants Upon Exercise.  If this Warrant shall have been exercised in part, the Company shall, at the request of
a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a
new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new
Warrant shall in all other respects be identical with this Warrant.

 

    4

     

    

 

iii.            Rescission
Rights.  If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by
the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

 

iv.            Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise.  In addition to any other rights available to the
Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date (other than as a result
of failure of the Holder to timely deliver the aggregate Exercise Price, unless the Warrant is validly exercised by means of a
cashless exercise), and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise)
or the Holder’s brokerage firm otherwise purchases, Common Shares to deliver in satisfaction of a sale by the Holder of the
Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall
(A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including brokerage
commissions, if any) for the Common Shares so purchased exceeds (y) the amount obtained by multiplying (1) the number
of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the
price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either
reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which
case such exercise shall be deemed rescinded) or deliver to the Holder the number of Common Shares that would have been issued
had the Company timely complied with its exercise and delivery obligations hereunder.  For example, if the Holder purchases
Common Shares having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of this Warrant
to purchase Common Shares with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of
the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company
written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence
of the amount of such loss.  Nothing herein shall limit a Holder’s right to pursue any other remedies available to it
hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect
to the Company’s failure to timely deliver Common Shares upon exercise of the Warrant as required pursuant to the terms hereof.

 

v.            No
Fractional Shares or Scrip.  No fractional shares or scrip representing fractional shares shall be issued upon the
exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon
such exercise, the Company shall round down to the nearest whole share.

 

    5

     

    

 

 

vi.            Charges,
Taxes and Expenses.  Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax
or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by
the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the
Holder; provided, however, that in the event that Warrant Shares are to be issued in a name other than the name of
the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed
by the Holder (along with a medallion guarantee if requested by the Company) and the Company may require, as a condition thereto,
the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.  The Company shall pay all Transfer
Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another
established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.

 

vii.            Closing
of Books.  The Company will not close its shareholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.

 

e)            Holder’s
Exercise Limitations.  The Company shall not effect any exercise of this Warrant, and a Holder shall not have the
right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving
effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the
Holder’s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s
Affiliates (such Persons, “Attribution Parties”)), would beneficially own in excess of the Beneficial
Ownership Limitation (as defined below).  For purposes of the foregoing sentence, the number of Common Shares
beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of Common Shares
issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number
of Common Shares which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the
unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other 
Common Share Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein
beneficially owned by the Holder or any of its Affiliates or Attribution Parties.  For purposes of this
Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act
and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not
representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the
Holder is solely responsible for any schedules required to be filed in accordance therewith.   To the extent that
the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in
relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion
of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise
shall be deemed to be the Holder’s determination of whether this Warrant is exercisable (in relation to other
securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is
exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify
or confirm the accuracy of such determination, and a submission of a Notice of Exercise shall be deemed a representation and
warranty by the Holder of the foregoing determination.   In addition, a determination as to any group status as
contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and
regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding Common
Shares, a Holder may rely on the number of outstanding Common Shares as reflected in (A) the Company’s most recent
periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the
Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of Common
Shares outstanding.  Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm
orally and in writing to the Holder the number of Common Shares then outstanding.  In any case, the number of
outstanding Common Shares shall be determined after giving effect to the conversion or exercise of securities of the Company,
including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of
outstanding Common Shares was reported.  The “Beneficial Ownership Limitation” shall be 4.99% (or,
upon election by the Holder prior to the issuance of any Warrants, 9.99%) of the number of the Common Shares outstanding
immediately after giving effect to the issuance of Common Shares issuable upon exercise of this Warrant.  The Holder,
upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this
Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of the Common
Shares outstanding immediately after giving effect to the issuance of Common Shares upon exercise of this Warrant held by the
Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership
Limitation will not be effective until the 61st day after such notice is delivered
to the Company.  The provisions of this paragraph shall be construed and implemented in a manner otherwise than in
strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may
be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or
supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph
shall apply to a successor holder of this Warrant.

 

    6

     

    

 

Section 3.     Certain
Adjustments.

 

a)            Stock
Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions on its Common Shares or any other equity or equity equivalent securities
payable in Common Shares (which, for avoidance of doubt, shall not include any Common Shares issued by the Company upon
exercise of this Warrant), (ii) subdivides outstanding Common Shares into a larger number of shares, (iii) combines
(including by way of reverse stock split) outstanding Common Shares into a smaller number of shares or (iv) issues by
reclassification of the Common Shares any shares of capital stock of the Company, then in each case the Exercise Price shall
be multiplied by a fraction of which the numerator shall be the number of Common Shares (excluding treasury shares, if any)
outstanding immediately before such event and of which the denominator shall be the number of Common Shares
outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be
proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged.  Any adjustment
made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination
of shareholders entitled to receive such dividend or distribution and shall become effective immediately after the effective
date in the case of a subdivision, combination or re-classification.

 

    7

     

    

 

b)            Subsequent
Rights Offerings.  In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company
grants, issues or sells any Common Share Equivalents or rights to purchase stock, warrants, securities or other property pro rata
to the record holders of any class of Common Shares (the “Purchase Rights”), then the Holder will be entitled
to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired
if the Holder had held the number of Common Shares acquirable upon complete exercise of this Warrant (without regard to any limitations
on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record
is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record
holders of Common Shares are to be determined for the grant, issue or sale of such Purchase Rights (provided, however,
that, to the extent that the Holder’s right to participate in any such Purchase Right would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent
(or beneficial ownership of such Common Shares as a result of such Purchase Right to such extent) and such Purchase Right to such
extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding
the Beneficial Ownership Limitation).

 

c)            Pro
Rata Distributions.  During such time as this Warrant is outstanding, if the Company shall declare or make any dividend
or other distribution of its assets (or rights to acquire its assets) to holders of Common Shares, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of
a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) except to
the extent an adjustment was already made pursuant to Section 3(a) (a “Distribution”), then the Exercise
Price shall be decreased, effective immediately after the effective date of such Distribution, by the amount of cash and/or the
fair market value (as determined by the Company’s Board of Directors, in good faith) of any securities or other assets paid
on each Common Share in respect of such Distribution in order that subsequent thereto upon exercise of the Warrants the Holder
may obtain the equivalent benefit of such Distribution.

 

    8

     

    

 

d)            Fundamental
Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or
more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the
Company (and all of its Subsidiaries, taken as a whole), directly or indirectly, effects any sale, lease, license,
assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related
transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or
another Person) is completed pursuant to which holders of Common Shares are permitted to sell, tender or exchange
their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding
Common Shares, (iv) the Company, directly or indirectly, in one or more related transactions effects any
reclassification, reorganization or recapitalization of the Common Shares or any compulsory share exchange pursuant to which
the Common Shares are effectively converted into or exchanged for other securities, cash or property, or (v) the
Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other
business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of
arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the
outstanding Common Shares (not including any Common Shares held by the other Person or other Persons making or party to, or
associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business
combination) (each a “Fundamental Transaction”), then, upon any subsequent exercise of this Warrant, the
Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately
prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in
Section 2(e) on the exercise of this Warrant), the number of Common Shares of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate
Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of Common Shares
for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in
Section 2(e) on the exercise of this Warrant).  For purposes of any such exercise, the determination of the
Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate
Consideration issuable in respect of one Common Share in such Fundamental Transaction, and the Company shall apportion the
Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different
components of the Alternate Consideration.  If holders of Common Shares are given any choice as to the securities, cash
or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate
Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.  Notwithstanding
anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below)
shall, at the Holder’s option, exercisable at any time concurrently with, or within 30 days after, the consummation of
the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction),
purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined
below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental
Transaction.  “Black Scholes Value” means the value of this Warrant based on the Black-Scholes Option
Pricing Model obtained from the “OV” function on Bloomberg, L.P. (“Bloomberg”) determined as
of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free
interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public
announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B) an expected volatility
equal to the greater of 100% and the 30 day volatility obtained from the HVT function on Bloomberg (determined utilizing a
365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable
contemplated Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater
of (i) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if
any, being offered in such Fundamental Transaction and (ii) the greater of (x) the last VWAP immediately prior to
the public announcement of such contemplated Fundamental Transaction and (y) the last VWAP immediately prior to the
consummation of such Fundamental Transaction, (D) a remaining option time equal to the time between the date of the
public announcement of the applicable contemplated Fundamental Transaction and the Termination Date and (E) a zero cost
of borrow.  The payment of the Black Scholes Value will be made by wire transfer of immediately available funds within
five Business Days of the Holder’s election (or, if later, on the effective date of the Fundamental Transaction). The
Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the
 “Successor Entity”) to assume in writing all of the obligations of the Company under this Warrant in
accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably
satisfactory to the Holder and approved by the Holders holding Warrants to purchase at least a majority of the Common Shares
underlying the then outstanding Warrants (without unreasonable delay) prior to such Fundamental Transaction and shall, at the
option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a
written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding
number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the Common Shares acquirable
and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to
such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital
stock (but taking into account the relative value of the Common Shares pursuant to such Fundamental Transaction and the value
of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of
protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and
which is reasonably satisfactory in form and substance to the Holders holding Warrants to purchase at least a majority of the
Common Shares underlying the then outstanding Warrants. Upon the occurrence of any such Fundamental Transaction, the
Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction,
the provisions of this Warrant referring to the “Company” shall refer instead to the Successor Entity), and may
exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with
the same effect as if such Successor Entity had been named as the Company herein.

 

    9

     

    

 

e)            Calculations.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may
be. For purposes of this Section 3, the number of Common Shares deemed to be issued and outstanding as of a given date shall
be the sum of the number of Common Shares (excluding treasury shares, if any) issued and outstanding.

 

f)            Notice
to Holder.

 

i.            Adjustment
to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such
adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts
requiring such adjustment.

 

ii.            Notice
to Allow Exercise by Holder. If (A) the Company shall declare a Distribution on the Common Shares, (B) the Company
shall declare a special nonrecurring cash dividend on or a redemption of the Common Shares, (C) the Company shall authorize
the granting to all holders of the Common Shares rights or warrants to subscribe for or purchase any shares of capital stock of
any class or of any rights, (D) the approval of any shareholders of the Company shall be required in connection with any reclassification
of the Common Shares, any consolidation or merger to which the Company (and its Subsidiaries, taken as a whole) is a party, any
sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common
Shares are converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary
dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered
by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register
of the Company, at least 10 Trading Days prior to the applicable record or effective date hereinafter specified, a notice stating
(x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants,
or if a record is not to be taken, the date as of which the holders of the Common Shares of record to be entitled to such dividend,
distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation,
merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that
holders of the Common Shares of record shall be entitled to exchange their Common Shares for securities, cash or other property
deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver
such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice.  To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public
information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission
pursuant to a Current Report on Form 6-K. The Holder shall remain entitled to exercise this Warrant during the period commencing
on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth
herein.

 

    10

     

    

 

g)            Voluntary
Adjustment by Company.  Subject to the rules and regulations of the Trading Market, the Company may at any time during
the term of this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by
the board of directors of the Company.

 

Section 4.     Transfer
of Warrant.

 

a)            Transferability. 
Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and
to the provisions of the Purchase Agreement, this Warrant and all rights hereunder are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written
assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney
(along with a medallion guarantee if requested by the Company) and funds sufficient to pay any transfer taxes payable upon
the making of such transfer.  Upon such surrender and, if required, such payment, the Company shall execute and deliver
a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this
Warrant not so assigned, and this Warrant shall promptly be cancelled.  Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this
Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of
the date on which the Holder delivers an assignment form (along with a medallion guarantee if requested by the Company) to
the Company assigning this Warrant in full.  The Warrant, if properly assigned in accordance herewith, may be exercised
by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

 

    11

     

    

 

b)            New
Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the
Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney.  Subject to compliance with Section 4(a), as to any transfer which may be involved
in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or
Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated
the Issue Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

 

c)            Warrant
Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant
Register”), in the name of the record Holder hereof from time to time.  The Company may deem and treat the registered
Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and
for all other purposes.

 

d)            Transfer
Restrictions. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer
of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act
and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions
or current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such
transfer, that the Holder or transferee of this Warrant, as the case may be, comply with the provisions of Section 4.1 of
the Purchase Agreement.

 

e)            Representation
by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is an “accredited
investor” (as defined by Regulation D promulgated under the Securities Act) and is acquiring this Warrant and, upon any
exercise hereof, will be an accredited investor and will acquire the Warrant Shares issuable upon such exercise, for its own
account and not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation
of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the
Securities Act.

 

Section 5.     Miscellaneous.

 

a)            No
Rights as Shareholder Until Exercise; No Settlement in Cash.  This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a shareholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except
as expressly set forth in Section 3.  Without limiting any rights of a Holder to receive Warrant Shares on a “cashless
exercise” pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein,
in no event shall the Company be required to net cash settle an exercise of this Warrant.

 

    12

     

    

 

 

 

 

b)            Loss,
Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of an affidavit of loss
reasonably satisfactory to the Company evidencing the loss, theft, destruction or mutilation of this Warrant or any stock certificate
relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to
it (which, in the case of the Warrant, shall not include the posting of a bond), and upon surrender and cancellation of such Warrant
or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated
as of such cancellation, in lieu of such Warrant or stock certificate.

 

c)            Saturdays,
Sundays, Holidays, etc.  If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next
succeeding Trading Day.

 

d)            Authorized
Shares.

 

The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Shares a sufficient
number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. 
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged
with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant.  The Company
will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without
violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Shares may be
listed.  The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented
by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance
herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by
the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such
issue).

 

Except and to the extent
as waived or consented to by the holders of a majority of the then outstanding Warrants (based on the number of Warrant Shares
underlying such Warrants) which are not beneficially owned by Affiliates of the Company, the Company shall not by any action, including,
without limitation, amending its articles of incorporation or through any reorganization, transfer of assets, consolidation, merger,
dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of
any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking
of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment;
provided, however, that no modification of the terms (including but not limited to the adjustments described in Section 3)
upon which the Warrants are exercisable or the rights of holders of Warrants to receive liquidated damages or other payments in
cash from the Company or reducing the percentage required for consent to modification of this Warrant may be made without the consent
of the Holder of each outstanding Warrant affected thereby.  Without limiting the generality of the foregoing, the Company
will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately
prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use
commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having
jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.

 

    13

     

    

 

Before taking any action
which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public
regulatory body or bodies having jurisdiction thereof.

 

e)            Governing
Law.  All questions concerning the construction, validity, enforcement and interpretation
of this Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of New York,
without regard to the principles of conflicts of law thereof.

 

f)             Jurisdiction;
Agent for Process. Each party agrees that all legal proceedings concerning the
interpretations, enforcement and defense of the transactions contemplated by this Warrant (whether brought against a party
hereto or their respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be
commenced exclusively in the state and federal courts sitting in the City of New York.  Each party hereby irrevocably
submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan
for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or
discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that
it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an
inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to
process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or
overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant
and agrees that, subject to applicable law, such service shall constitute good and sufficient service of process and notice
thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner
permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the
prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable
attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such
action or proceeding. Notwithstanding the foregoing, nothing in this paragraph shall limit or restrict the federal district
court and the state court in which a Holder may bring a claim under the federal securities laws. The Company hereby
irrevocably designates and appoints Watson Farley & Williams LLP, 250 West 55th Street, 31st Floor, New York, New
York 10019 (the “Process Agent”) as its authorized agent upon whom process may be served in any claim
brought against the Company, it being understood that the designation and appointment of the Process Agent as such authorized
agent shall become effective immediately without any further action on the part of the Company. The Company represents to
each Purchaser that it has notified the Process Agent of such designation and appointment and that the Process Agent has
accepted the same.  The Company hereby irrevocably authorizes and directs the Process Agent to accept such
service.

 

    14

     

    

 

g)             Restrictions. 
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered and the Holder does
not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.

 

h)             Nonwaiver
and Expenses.  No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies.  Without limiting
any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant,
which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to
cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings,
incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies
hereunder.

 

i)              Notices. 
Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation,
any Notice of Exercise, shall be in writing and delivered personally, by facsimile, e-mail or sent by a nationally recognized overnight
courier service, addressed to:

 

If to the Company

 

Globus Maritime Limited 

128 Vouliagmenis Avenue, 3rd Floor 

166 74 Glyfada 

Athens, Greece 

Tel: +30 210 960 8300 

Email: a.g.feidakis@globusmaritime.gr 

Facsimile: +30 210 9608359 

Attn: Chief Executive Officer

 

or such other facsimile number, email address
or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications or
deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by facsimile or e-mail, or sent
by a nationally recognized overnight courier service addressed to each Holder at the facsimile number, e- mail address or address
of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed
given and effective on the earliest of (a) the time of transmission, if such notice or communication is delivered via facsimile
at the facsimile number or e-mail attachment at the email address set forth on the signature pages attached hereto at or prior
to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the date of transmission, if such
notice or communication is delivered via facsimile at the facsimile number or e-mail attachment at the e-mail address as set forth
on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time)
on any Trading Day, (c) the second (2nd) Trading Day following the date of mailing, if sent by U.S. nationally recognized
overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given.

 

    15

     

    

 

j)              Limitation
of Liability.  No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to
purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability
of the Holder for the purchase price of any Common Share or as a shareholder of the Company, whether such liability is asserted
by the Company or by creditors of the Company.

 

k)             Remedies. 
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled
to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation
for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert
the defense in any action for specific performance that a remedy at law would be adequate.

 

l)              Successors
and Assigns.  Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted
assigns of Holder.  The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this
Warrant and shall be enforceable by the Holder or holder of Warrant Shares.

 

m)            Amendment. 
This Warrant may be modified or amended (or the provisions hereof waived) by the Holders holding Warrants to purchase at least
a majority of the Common Shares underlying the then outstanding Warrants.

 

n)             Severability. 
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective
to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions
of this Warrant.

 

o)             Headings. 
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of
this Warrant.

 

********************

 

(Signature Page Follows)

 

    16

     

    

 

 

IN WITNESS WHEREOF,
the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

 

	 	GLOBUS MARITIME LIMITED
	 	 	 
		By:	

	 	 	Name:	 
	 	 	Title:	 

 

    17

     

    

 

NOTICE OF EXERCISE

 

	TO:	GLOBUS MARITIME LIMITED

 

(1)         The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
required if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer
taxes, if any.

 

(2)         Payment
shall take the form of (check applicable box):

 

[  ] wire transfer in lawful money
of the United States; or

 

[   ] if permitted, the cancellation
of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this
Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth
in subsection 2(c).

 

(3)         Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

The Warrant Shares
shall be delivered to the following DWAC Account Number:

 

	DTC number:	 	 
	Account name:	 	 
	Account number:	 	 

 

(4)         The undersigned
is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933, as amended, and
is acquiring the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or
reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except
pursuant to sales registered or exempted under the Securities Act.

 

[SIGNATURE OF HOLDER]

 

	Name of Investing Entity:	 
	Signature of Authorized Signatory of Investing Entity:	 
	Name of Authorized Signatory:	 
	Title of Authorized Signatory:	 
	Date:	 

 

    18

     

    

 

EXHIBIT B

 

ASSIGNMENT FORM

 

(To assign the foregoing Warrant, execute
this form and supply required information.  Do not use this form to purchase shares.)

 

FOR VALUE RECEIVED,
the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

	Name:	 
	 	(Please Print)
	Address:	 
	 	(Please Print)
	Phone Number:	 
	Email Address:	 
	Dated: _______________ __, ______	 
	Holder’s Signature: _______________	 
	Holder’s Address: _______________EXHIBIT
10.01

 

EMPLOYMENT
AGREEMENT

 

THIS
EMPLOYMENT AGREEMENT (“Agreement”) is entered into as of July 15, 2020 by and between LIXTE BIOTECHNOLOGY
HOLDINGS INC., a Delaware corporation having its principal place of business located at 248 Route 25A, No. 2, East Setauket,
NY 11733 (“Company”), and JOHN S. KOVACH(“Employee”), an individual
residing at 6 Tinker Lane, East Setauket, NY 11733.

 

WHEREAS,
Employer desires to employ Employee and Employee desires to enter into such employment upon the terms and conditions hereinafter
set forth;

 

Agreement

 

In
consideration of the mutual promises contained herein, the parties agree as follows:

 

1.
Services and Compensation. Employee agrees to perform for the Company the services described in Exhibit A (the “Services”),
and the Company agrees to pay Employee the compensation described in Exhibit A for Employee’s performance of the
Services. If not specified on Exhibit A, the scope, timing, duration, and site of performance of said Services shall be
mutually and reasonably agreed to by the Company and Employee and are subject to change upon the written agreement of both parties.
Employee will make reasonable, good faith efforts to provide the Services in a timely and professional manner consistent with
industry practices. Employee shall report to the Company’s Board of Directors. Employee shall devote his full time and efforts
to the performance of his responsibilities as the Chief Executive Officer of a publicly held company. Except as set forth on Exhibit
A, the Company shall have no obligation to provide any compensation to Employee with respect to any Services rendered by Employee
to the Company pursuant to this Agreement.

 

2.
Confidentiality.

 

2.1
Definitions. “Confidential Information” means all data, studies, reports, information, technology, samples
and specimens relating to the Company or its plans, products, product concepts, formulas, technologies, business, financial, marketing,
research, non-clinical, clinical or regulatory affairs, manufacturing processes and procedures, or those of any other third party,
from whom the Company receives information on a confidential basis, whether written, graphic or oral, furnished to Employee by
or on behalf of the Company, either directly or indirectly, or obtained or observed by Employee while providing services hereunder,
and the Services to be provided by Employee hereunder. Confidential Information does not include (i) information that is now in
the public domain or subsequently enters the public domain and is generally available without fault on the part of Employee; (ii)
information that is presently known by Employee from Employee’s own sources as evidenced by Employee’s prior written
records; or (iii) information disclosed to Employee by a third party legally and contractually entitled to make such disclosures.

 

    	 

     

    

 

2.2
Nonuse and Nondisclosure. Employee will not, during or subsequent to the Term (as defined below), (i) use the Confidential
Information for any purpose whatsoever other than the performance of the Services on behalf of the Company or (ii) disclose the
Confidential Information to any third party. Employee agrees that, as between the Company and Employee, all Confidential Information
will remain the sole property of the Company. Employee also agrees to take all necessary and reasonable precautions to prevent
any unauthorized disclosure of such Confidential Information. Without the Company’s prior written approval, Employee may
disclose the existence, but not the terms, of this Agreement to third parties. Anything to the contrary notwithstanding, Employee
may also disclose Confidential Information to the extent such disclosure is required by a court of competent jurisdiction and
provided that Employee promptly notifies the Company of such requirement. Employee acknowledges that the use or disclosure of
Confidential Information without the Company’s express written permission will cause the Company irreparable harm and that
any material breach or threatened material breach of this Agreement by Employee will entitle the Company to seek injunctive relief
and reasonable attorneys’ fees, in addition to any other legal remedies available to it, in any court of competent jurisdiction.

 

2.3
Third Party Confidential Information. Employee recognizes that the Company has received and in the future may receive from
third parties, their confidential or proprietary information subject to a duty on the Company’s part to maintain the confidentiality
of such information and to use it only for certain limited purposes. Employee agrees that, during the Term of this Agreement and
thereafter, Employee will hold, and that Employee owes the Company and such third parties a duty to hold, all such confidential
or proprietary information in the strictest confidence and not to disclose it to any person, firm or entity or to use it except
as necessary in carrying out the Services for the Company consistent with the Company’s agreement with such third party,
unless otherwise authorized by such third party.

 

2.4
Return of Materials. At any time upon the Company’s request, Employee will deliver to the Company all of the Company’s
property, equipment and documents, together with all copies thereof, that were previously provided to Employee or created by Employee
for the Company pursuant to the Services, including but not limited to all electronically stored confidential and/or nonpublic
information, passwords to access such property, or Confidential Information that Employee may have in Employee’s possession
or control, and Employee agrees to certify in writing that Employee has fully complied with this obligation.

 

2.5
No Improper Disclosure or Use of Materials. Employee will not improperly use or disclose to, or for the benefit of, the Company
any confidential information or trade secrets of (i) any former, current or future employer, (ii) any person to whom Employee
has previously provided, currently provides or may in the future provide services, or (iii) any other person to whom Employee
owes an obligation of confidentiality. Employee will not bring onto the premises of the Company any unpublished documents or any
property belonging to any person referred to in the foregoing clauses (i)-(iii) of this Section 2.5 unless consented to in writing
by such person. Without limiting the generality of the foregoing, Employee will not disclose to the Company, and will not use
for the benefit of the Company, any information relating to or arising out of Employee’s work conducted at his present employer,
or utilizing the funds, personnel, facilities, materials or other resources of his present employer, until such information has
been published.

 

    	2 of 8

     

    

 

2.6
Non-Exclusivity of Confidentiality Obligations. The obligations of Employee under this Section 2 are without prejudice, and
are in addition to, any other obligations or duties of confidentiality, whether express or implied or imposed by applicable law,
that are owed to the Company or any other person to whom the Company owes an obligation of confidentiality.

 

3.
Ownership.

 

3.1
Assignment. Employee agrees that all copyrights and copyrightable material, notes, records, drawings, designs, inventions,
ideas, discoveries, enhancements, modifications, know-how, improvements, developments, discoveries, trade secrets, data and information
of every kind and description conceived, generated, made, discovered, developed or reduced to practice by Employee, solely or
in collaboration with others, during the Term and in the course of performing Services under this Agreement (collectively, “Inventions”),
are, as between the Company and Employee, the sole and exclusive property of the Company. Employee agrees to disclose such Inventions
promptly to the Company and hereby assigns, and agrees to assign, all of Employee’s right, title and interest in and to
any such Inventions promptly to the Company without royalty or any other consideration and to execute all applications, assignments
or other instruments reasonably requested by the Company in order for the Company to establish the Company’s ownership of
such Inventions and to obtain whatever protection for such Inventions, including copyright and patent rights in any and all countries
on such Inventions as the Company shall determine.

 

3.2
Further Assurances. Employee agrees to assist the Company, or its designee, in every reasonable way to secure the Company’s
rights in Inventions and any copyrights, patents or other intellectual property rights relating to all Inventions (“Proprietary
Rights”) in any and all countries, including the disclosure to the Company of all pertinent information and data
with respect to all Inventions, the execution of all applications, specifications, oaths, assignments and all other instruments
that the Company may deem necessary in order to apply for and obtain such rights and in order to assign and convey to the Company,
its successors, assigns and nominees the sole and exclusive right, title and interest in and to all Inventions, and any copyrights,
patents, or other intellectual property rights relating to all Inventions. Employee also agrees that Employee’s obligation
to execute or cause to be executed any such instrument or papers shall continue after the termination of this Agreement.

 

3.3
Pre-Existing Materials. Subject to Section 3.1, Employee agrees that if, in the course of performing the Services, Employee
incorporates into any Invention developed under this Agreement any pre-existing invention, improvement, development, concept,
discovery or other proprietary information owned by Employee or in which Employee has an interest, (i) Employee will inform the
Company, in writing before incorporating such invention, improvement, development, concept, discovery or other proprietary information
into any Invention, and (ii) the Company is hereby granted a nonexclusive, royalty-free, perpetual, irrevocable, worldwide license
to make, have made, modify, use and sell such item as part of or in connection with such Invention. Employee will not incorporate
any invention, improvement, development, concept, discovery or other proprietary information owned by any third party into any
Invention without the Company’s prior written permission.

 

    	3 of 8

     

    

 

3.4
Attorney-in-Fact. Employee agrees that, if the Company is unable because of Employee’s unavailability, dissolution,
mental or physical incapacity, or for any other reason, to secure Employee’s signature for the purpose of applying for or
pursuing any application for any United States or foreign patents, mask work or copyright registrations covering the Inventions
assigned to the Company in Section 3.1, then Employee hereby irrevocably designates and appoints the Company and its duly authorized
officers and agents as Employee’s agent and attorney-in-fact, to act for and on Employee’s behalf to execute and file
any such applications and to do all other lawfully permitted acts only to further the prosecution and issuance of patents, copyright
and mask work registrations with the same legal force and effect as if executed by Employee.

 

3.5
Waiver; Non-Exclusivity of Obligations. Employee hereby waives and quitclaims to the Company any and all claims of any nature
whatsoever that Employee may now or hereafter have for infringement of any Inventions and Proprietary Rights assigned hereunder
to the Company. Without the prior written consent of the Company, Employee will not, at any time, file any patent or copyright
application with respect to, or claiming, any Inventions. The obligations of Employee under this Section 5 are without prejudice,
and are in addition to, any other obligations or duties of Employee, whether express or implied or imposed by applicable law,
to assign to the Company all Inventions and all Proprietary Rights.

 

4.
Representations and Warranties. Employee represents and warrants to the Company that: Employee is legally able to enter into
this Agreement and that Employee’s execution, delivery and performance of this Agreement will not and does not conflict
with any agreement, arrangement or understanding, written or oral, to which Employee is a party or by which Employee is bound;
Employee is under no physical or mental disability that would hinder his performance of the professional duties to be rendered
by Employee under this Agreement; Employee is not a party to any civil, criminal or administrative suits or proceedings, or aware
of any threatened actions of such a nature; Employee has never been convicted of a crime, is not now under indictment, and is
unaware of any such threatened actions; and Employee has never been subjected to disciplinary proceedings or investigation by
any State agency or other governmental agency.

 

5.
Term and Termination.

 

5.1
Term. The term of this Agreement (the “Term”) shall commence on October 1, 2020 (the “Effective
Date”), and shall remain in full force and effect until the earlier of (i) one year from the Effective Date, automatically
renewable for additional one year periods unless terminated by either party upon sixty (60) days written notice prior to the end
of an applicable one year period, (ii) Employee’s death or (iii) termination as provided in Section 5.2.

 

5.2
Termination. The Company may terminate this Agreement immediately and without prior notice if Employee refuses to or is unable
to perform the Services or is in breach of any material provision of this Agreement and fails to cure such breach (if such breach
is curable) within thirty days of notice of such breach by the Company.

 

    	4 of 8

     

    

 

5.3
Survival. Upon termination of this Agreement, all rights and duties of the Company and Employee toward each other shall cease
except:

 

(a)
The Company will pay, within 30 days after the effective date of termination, all amounts owing to Employee for Services completed
and accepted by the Company prior to the termination date and related expenses, if any, submitted in accordance with the Company’s
policies and in accordance with the provisions of Section 1 of this Agreement; and

 

6.
Benefits; Taxes.

 

6.1
Benefits. The Company and Employee agree that Employee will receive no Company-sponsored benefits from the Company, except
those mandated by state or federal law.

 

6.2
Taxes and Withholdings. Employee’s compensation shall be payable in accordance with the general practice of the Employer
for professional employees and shall be subject to all applicable withholding taxes.

 

7.
Indemnification. The Company shall defend, indemnify and hold Employee harmless from and against any and all claims, demands,
losses, damages, liabilities (including without limitation product liability), settlement amounts, costs and expenses whatsoever
(including without limitation reasonable attorneys’ fees and costs and including, without limitation, product liability
claims) arising from or relating to any claim, action or proceeding made or brought against Employee or the Company as a result
of, or associated with, the development, use, manufacture, marketing or sale of products regarding which Employee has provided
Services unless such liability arises from Employee’s or Employee’s assistants’, employees’ or agents’
negligence, intentional misconduct or breach of this Agreement.

 

8.
Non-Compete; Nonsolicitation; Non-Disclosure.

 

8.1
Non-Compete. During the Term, Employee will not, without the Company’s prior written consent, become employed by or
render services to any other person or entity engaged in the business of developing or marketing drug programs focusing on inhibitors
of protein phosphatases (a “Competing Business”). Notwithstanding the foregoing, the Company consents to Employee
being employed by the City of Hope National Medical Center.

 

8.2
Nonsolicitation. During the Term and and for a period of six month thereafter (the “Restricted Period”), Employee
will not, without the Company’s prior written consent, directly or indirectly, whether for Employee’s own account
or for the account of any other person, firm, corporation or other business organization, solicit, entice, persuade, induce or
otherwise attempt to influence any person or business who is, or during the period of Employee’s engagement by the Company
was, an employee, Employee, contractor, partner, supplier, customer or client of the Company or its affiliates to leave or otherwise
stop doing business with the Company.

 

8.3
Non-Disclosure. Employee agrees that without the prior written consent of the Company, Employee will not intentionally generate
any publicity, news release or other announcement concerning the engagement of Employee hereunder or the services to be performed
by Employee hereunder or otherwise utilize the name of the Company or any of its affiliates for any advertising or promotional
purposes.

 

    	5 of 8

     

    

 

8.4
Reasonableness of Restrictions. Employee hereby acknowledges and agrees that the foregoing restrictions contained in this
Section 8 are reasonable, proper and necessitated by the legitimate business interests of the Company and will not prevent Employee
from earning a living or pursuing his or her career. In the event that a court finds this Section 8, or any of its restrictions,
to be unenforceable or invalid, Employee and the Company hereby agree that (i) this Section 8 will be automatically modified to
provide the Company with the maximum protection of its business interests allowed by law and (ii) Employee shall be bound, and
such court shall enforce, this Section 8 as so modified.

 

9.
Voluntary Nature of Agreement. Employee acknowledges and agrees that Employee is executing this Agreement voluntarily and
without any duress or undue influence by the Company or anyone else. Employee further acknowledges and agrees that Employee has
carefully read this Agreement and has asked any questions needed to understand the terms, consequences and binding effect of this
Agreement and fully understand it to his or her satisfaction. Finally, Employee agrees that Employee has been provided an opportunity
to seek the advice of an attorney of its choice before signing this Agreement.

 

10.
Remedies. Employee acknowledges and agrees that the agreements and restrictions contained in Sections 2, 3 and 8 are necessary
for the protection of the business and goodwill of the Company and are reasonable for such purpose. Employee acknowledges and
agrees that any breach of the provisions of Sections 2, 3 and 8 may cause the Company substantial and irreparable damage for which
the Company cannot be adequately compensated by monetary damages alone, and, therefore, in the event of any such breach, in addition
to such other remedies which may be available, the Company shall have the right to seek specific performance and injunctive relief
without the necessity of proving actual damages. However, if the Company claims that Employee breached any of Sections 2, 3 and
8, nothing herein shall relieve the Company of the burden of proving that Employee failed to abide by Section 2, 3 or 8.

 

11.
Miscellaneous.

 

11.1
Governing Law. This Agreement shall be governed by the laws of Delaware without regard to conflicts of law rules.

 

11.2
Assignability. Except as otherwise provided in this Agreement, Employee may not sell, assign or delegate any rights or obligations
under this Agreement.

 

11.3
Entire Agreement. This Agreement constitutes the entire agreement between the parties with respect to the subject matter of
this Agreement and supersedes all prior written and oral agreements between the parties regarding the subject matter of this Agreement.

 

11.4
Headings. Headings are used in this Agreement for reference only and shall not be considered when interpreting this Agreement.

 

11.5
Notices. Any notice or other communication required or permitted by this Agreement to be given to a party shall be in writing
and shall be deemed given if delivered personally or by commercial messenger or courier service, or mailed by U.S. registered
or certified mail (return receipt requested). If by mail, delivery shall be deemed effective 3 business days after mailing in
accordance with this Section 11.5.

 

    	6 of 8

     

    

 

If
to the Company, to:

 

Lixte
Biotechnology Holdings, Inc.

Attention:
Eric Forman

Chief
Administrative Officer

248
Route 25A, No. 2

East
Setauket, NY 11733

 

If
to Employee, to:

 

John
S. Kovach, MD

6
Tinker Lane

East
Setauket, NY 11733

 

The
address for notice on the signature page to this Agreement or, if no such address is provided, to the last address of Employee
provided by Employee to the Company.

 

11.6
Amendments; Waiver. No modification of or amendment to this Agreement, or any waiver of any rights under this Agreement, will
be effective unless in writing and signed by Employee and the Company.

 

11.7
Attorneys’ Fees. In any court action at law or equity that is brought by one of the parties to this Agreement to enforce
or interpret the provisions of this Agreement, the prevailing party will be entitled to reasonable attorneys’ fees, in addition
to any other relief to which that party may be entitled.

 

11.8
Further Assurances. Employee agrees, upon request, to execute and deliver any further documents or instruments necessary or
desirable to carry out the purposes or intent of this Agreement.

 

11.9
Severability. If any provision of this Agreement is found to be illegal or unenforceable, the other provisions shall remain
effective and enforceable to the greatest extent permitted by law.

 

11.10
Counterparts and Facsimiles. This Agreement may be executed in one or more counterparts, each of which shall be deemed an
original, but all of which taken together shall constitute one and the same instrument. Facsimile signatures shall be deemed original
signatures for all purposes.

 

11.11
Acknowledgement. EMPLOYEE UNDERSTANDS THAT THIS AGREEMENT AFFECTS HIS RIGHTS TO CERTAIN INVENTIONS, AND RESTRICTS HIS RIGHTS TO
DISCLOSE OR USE CONFIDENTIAL INFORMATION, AND TO COMPETE WITH THE COMPANY DURING, OR SUBSEQUENT TO, THE TERMINATION OF THIS AGREEMENT.

 

[Signature
Page Follows]

 

    	7 of 8

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Employment Agreement as of the date first written
above.

 

	EMPLOYEE	 	LIXTE
    BIOTECHNOLOGY
	 	 	 	HOLDINGS,
    INC. 
	 	 	 	 	  
	 		 	By:	
	Name:	John
    S. Kovach, MD	 	Name:	Eric
    Forman
	Address:	6
                                         Tinker Lane

                                                         East
                                         Setauket NY 11733
	 	Title:	Chief
    Administrative Officer

 

    	 

     

    

 

EXHIBIT
A

 

SERVICES
AND COMPENSATION

 

1.
Services. As President, Chief Scientific Officer & Chief Executive Officer Employee’s responsibilities shall
be for the oversight of the Company’s entire operations and strategic planning and shall be the primary contact between
the Company’s executive team and the Board of Directors, to whom he shall report. Employee shall supervise all scientific
endeavors, providing guidance to the Chief Medical Officer. Employee shall endeavor to create a corporate culture appropriate
to that of a publicly held corporation, shall be the principal spokesperson for the Companyshall have final say on all corporate
matters, subject only to the authority of the Board of Directors.

 

2.
Compensation.

 

	 	A.	The Company will
    pay Employee Two Hundred and Fifty Thousand Dollars ($250,000) annually, paid monthly. All amounts payable to Employee hereunder
    shall be net of any applicable withholding taxes.
	 	 	 
	 	B.	The Company will
    reimburse Employee for all reasonable expenses incurred by Employee in performing the Services pursuant to this Agreement,
    provided that Employee receives written consent from the Company’s CFO prior to incurring such expenses and submits
    receipts for such expenses to the Company in accordance with Company policy.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]